

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (the "Company") for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# **S.R. BATLIBOI & ASSOCIATES LLP**


Chartered Accountants

5. The comparative Ind AS financial information of the Company for the corresponding quarter and period ended December 31, 2022 included in these standalone Ind AS financial results, were reviewed/audited by the predecessor auditor and the standalone Ind AS financial statements of the Company for the year ended March 31, 2023, were audited by predecessor auditor who expressed an unmodified opinion on those financial information on February 09, 2023 and May 14, 2023 respectively.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

**ICAI Firm registration number: 101049W/E300004**



**per Atin Bhargava**

Partner

Membership No.: 504777

UDIN: 24504777BKD HKD5313



Hyderabad

January 24, 2024

## Rainbow Children's Medicare Limited (formerly known as 'Rainbow Children's Medicare Private Limited')

CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034  
 Corporate Office : 8-2-19/1/a, Daulat Arcade, Karvy lane, Road No.11, Banjara Hills, Hyderabad, Telangana-500034  
 Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

## Statement of Unaudited Standalone Financial Results for the quarter and year to date ended 31 December 2023

Particulars	(Rs. in Millions except per share data)					
	Quarter ended			Year to date ended		Year ended
	31 December 2023	30 September 2023	31 December 2022	31 December 2023	31 December 2022	31 March 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>INCOME</b>						
1. Revenue from operations	3,217.90	3,186.65	2,907.18	9,108.05	8,112.61	11,139.90
2. Other income	82.41	88.79	82.40	247.13	225.87	312.29
<b>3. Total income [1+2]</b>	<b>3,300.31</b>	<b>3,275.44</b>	<b>2,989.58</b>	<b>9,355.18</b>	<b>8,338.48</b>	<b>11,452.19</b>
<b>4. EXPENSES</b>						
a. Medical consumables and pharmacy items consumed	408.32	402.59	384.70	1,170.63	1,093.14	1,501.22
b. Employee benefits expense	412.76	384.89	366.22	1,213.32	978.01	1,360.38
c. Finance costs	135.19	125.85	128.58	399.53	387.82	520.89
d. Depreciation and amortisation expense	259.34	250.09	210.25	745.83	621.38	837.08
e. Professional fees to doctors	730.52	751.16	686.05	2,138.16	1,877.23	2,554.04
f. Other expenses	528.73	504.88	452.13	1,479.78	1,321.80	1,903.94
<b>Total expenses</b>	<b>2,474.86</b>	<b>2,419.46</b>	<b>2,227.93</b>	<b>7,147.25</b>	<b>6,279.38</b>	<b>8,677.55</b>
<b>5. Profit before exceptional items and tax [3-4]</b>	<b>825.45</b>	<b>855.98</b>	<b>761.65</b>	<b>2,207.93</b>	<b>2,059.10</b>	<b>2,774.64</b>
<b>6. Exceptional items</b>	-	-	-	-	46.30	46.30
<b>7. Profit before tax [5-6]</b>	<b>825.45</b>	<b>855.98</b>	<b>761.65</b>	<b>2,207.93</b>	<b>2,012.80</b>	<b>2,728.34</b>
<b>8. Tax expenses:</b>						
a. Current tax	228.59	232.10	223.92	608.06	601.78	811.41
b. Deferred tax credit	(14.55)	(15.96)	(31.04)	(44.68)	(92.07)	(142.00)
<b>Total tax expense</b>	<b>214.04</b>	<b>216.14</b>	<b>192.88</b>	<b>563.38</b>	<b>509.71</b>	<b>669.41</b>
<b>9. Profit for the period/year [7-8]</b>	<b>611.41</b>	<b>639.84</b>	<b>568.77</b>	<b>1,644.55</b>	<b>1,503.09</b>	<b>2,058.93</b>
<b>10. Other comprehensive income</b>						
<i>Items that will not be reclassified to profit or loss</i>						
Re-measurement gain on defined benefit plans	1.72	2.22	3.26	5.15	9.77	4.83
Income tax effect	(0.43)	(0.56)	(0.82)	(1.30)	(2.46)	(1.22)
<b>Other comprehensive income for the period/year, net of tax</b>	<b>1.29</b>	<b>1.66</b>	<b>2.44</b>	<b>3.85</b>	<b>7.31</b>	<b>3.61</b>
<b>11. Total comprehensive income for the period/year [9+10]</b>	<b>612.70</b>	<b>641.50</b>	<b>571.21</b>	<b>1,648.40</b>	<b>1,510.40</b>	<b>2,062.54</b>
<b>12. Paid-up equity share capital (Face value of Rs. 10 each)</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>
<b>13. Other equity</b>						<b>9,868.86</b>
<b>14. Earning per share (Face value of share Rs.10 each)</b>						
a. Basic (Rs)	6.03	6.30	5.63	16.20	14.89	20.40
b. Diluted (Rs)	6.03	6.30	5.63	16.20	14.89	20.40
	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	



**Notes :**

- The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by Audit Committee and approved by the Board of Directors at their respective meetings held on 24 January 2024. The Statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued an unmodified report thereon.
- Final dividend for the financial year 2022-23 of Rs. 3 per Equity Share of Rs. 10 each aggregating to Rs. 304.51 million was approved by the shareholders at the 25th Annual General Meeting held on 29 June 2023 and the same was paid on 04 July 2023.
- During the financial year 2022-23, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022. The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between Company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO expenses Rs. 138.60 million has been adjusted with securities premium as per Companies Act, 2013. During the quarter ended 30 September 2023, the Company has received an amount of Rs. 14.70 million towards the Company's share of unspent IPO expenses. The same has been adjusted with securities premium as per Companies Act, 2013. The Board of Directors of the Company in their meeting held on 30 October 2023 has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes, refer column (B) in the table below. After this change amount to be utilised for General corporate purposes is Rs. 576.10 million.

**Details of utilisation of IPO proceeds:**

(Rs. in Millions)

Objects of the issue	Amount as proposed in offer document	Amount to be spent as per offer document up to 31 March 2023 (A)	Reimbursement of Company's share of unspent IPO expenses (B)	Status as at 31 December 2023 for 31 March 2023			
				Revised amount to be spent (C) = (A) + (B)	Utilisation up to 31 December 2023 (D)	Unspent balance as at 31 December 2023 (E) = (C) - (D)	Reasons for delay in utilisation of IPO Proceeds
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-	400.00	400.00	-	NA
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	1,065.00	-	1,065.00	1,057.44	7.56	Delay in execution of few projects.
General corporate purposes	561.40	561.40	14.70	576.10	576.10	-	NA
<b>Total</b>	<b>2,661.40</b>	<b>2,026.40</b>	<b>14.70</b>	<b>2,041.10</b>	<b>2,033.54</b>	<b>7.56</b>	

Net IPO proceeds which were unutilised as at 31 December 2023 were temporarily invested in fixed deposits and held in current account with banks.

- Pursuant to the resolutions passed by the Board on 18 March 2023 and by the Shareholders on 06 May 2023, the Company approved 'Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBESE Regulations"). The Stock Unit Plan 2023 is for issue of employee stock units to eligible employees, which may result in an issuance of a maximum number of 400,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one Equity Share per employee stock unit.

Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held on 14 May 2023 and 07 August 2023, granted 275,000 and 37,414 Stock Units respectively under the Stock Unit Plan 2023 to its eligible employees which shall be exercisable into 312,414 equity shares having face value of Rs. 10 each fully paid-up. The exercise price per stock unit shall be the face value of equity shares of the Company i.e. Rs. 10 each. The vested Stock Units shall be exercisable within a period of three months from the date of each vesting. The Stock Units shall vest after the minimum vesting period of one year and not later than the maximum period of five years from the date of grant. The plan is in terms of SEBI SBESE Regulations.

- During the financial year 2022-23, the Company won the bid for 2 land parcels in Gurugram, Haryana admeasuring 9,391 Sq. Mtr. ~ 2.32 acres and 4,987.10 Sq. Mtr. ~ 1.23 acres, situated in Sector 44 and Sector 56 respectively auctioned by Haryana Shahari Vikas Pradhikaran (HSVP). On 05 July 2023, the Company has received the allotment letters from HSVP, for the allotment of said land parcels to the Company post payment of full consideration of Rs. 1,299.40 million and Rs. 290.40 million for land parcels situated in Sector 44 and Sector 56 respectively.
- The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- The standalone financial results for the quarter and year to date ended 31 December 2023, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).



for and on behalf of the Board of Directors of  
Rainbow Children's Medicare Limited

**Dr. Ramesh Kancharla**  
Chairman and Managing Director  
DIN: 00212270

Place : Hyderabad  
Date : 24 January 2024

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

**Holding company:**

Rainbow Children's Medicare Limited

**Subsidiaries:**

- a) Rainbow Speciality Hospitals Private Limited
- b) Rosewalk Healthcare Private Limited
- c) Rainbow C R O Private Limited
- d) Rainbow Fertility Private Limited
- e) Rainbow Children's Hospital Private Limited
- f) Rainbow Woman & Children's Hospital Private Limited



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes unaudited interim financial results in respect of 2 subsidiaries, whose unaudited interim financial results reflect total revenues of Rs 146.98 million and Rs. 465.98 million, total net profit after tax of Rs. 13.52 million and Rs. 38.56 million, and total comprehensive income of Rs. 13.70 million and Rs. 39.10 million, for the quarter ended December 31, 2023 and the period ended on that date respectively as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results in respect of 4 subsidiaries, whose interim financial results reflect total revenues of Rs 0.02 million and Rs. 2.14 million, total net profit after tax of Rs. 0.68 million and Rs. 3.23 million, and total comprehensive income of Rs. 0.68 million and Rs. 3.23 million, for the quarter ended December 31, 2023 and the period ended on that date respectively

The unaudited interim financial results of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.



# **S.R. BATLIBOI & ASSOCIATES LLP**


Chartered Accountants

8. The comparative Ind AS financial information of the Group for the corresponding quarter and period ended December 31, 2022, included in these consolidated Ind AS financial results, were reviewed/audited by the predecessor auditor and the Ind AS consolidated financial statements of the Group for the year ended March 31, 2023, were audited by predecessor auditor who expressed an unmodified opinion on those consolidated financial information on February 9, 2023 and May 14, 2023 respectively.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

**ICAI Firm registration number: 101049W/E300004**

  
per Atin Bhargava

Partner

Membership No.: 504777




UDIN: 24504777BKDHKE2007

Hyderabad

January 24, 2024

Statement of Unaudited Consolidated Financial Results for the quarter and year to date ended 31 December 2023

Particulars	(Rs. in Millions except per share data)					
	Quarter ended			Year to date ended		
	31 December 2023	30 September 2023	31 December 2022	31 December 2023	31 December 2022	Year ended 31 March 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>INCOME</b>						
1. Revenue from operations	3,359.58	3,326.75	3,064.04	9,557.98	8,566.08	11,735.74
2. Other income	86.09	78.23	83.71	242.87	219.67	308.65
<b>3. Total income [1+2]</b>	<b>3,445.67</b>	<b>3,404.98</b>	<b>3,147.75</b>	<b>9,800.85</b>	<b>8,785.75</b>	<b>12,044.39</b>
<b>4. EXPENSES</b>						
a. Medical consumables and pharmacy items consumed	426.97	422.45	402.38	1,233.41	1,155.45	1,582.78
b. Employee benefits expense	434.25	407.33	384.40	1,277.55	1,034.69	1,440.61
c. Finance costs	142.62	133.38	136.31	422.07	411.22	551.95
d. Depreciation and amortisation expense	276.60	267.96	231.80	797.84	675.38	902.68
e. Professional fees to doctors	772.11	794.85	736.56	2,265.35	2,003.77	2,723.05
f. Other expenses	545.47	526.51	473.14	1,548.24	1,388.47	2,025.53
<b>Total expenses</b>	<b>2,598.02</b>	<b>2,552.48</b>	<b>2,364.59</b>	<b>7,544.46</b>	<b>6,668.98</b>	<b>9,226.60</b>
<b>5. Profit before tax [3-4]</b>	<b>847.65</b>	<b>852.50</b>	<b>783.16</b>	<b>2,256.39</b>	<b>2,116.77</b>	<b>2,817.79</b>
<b>6. Tax expenses:</b>						
a. Current tax	235.67	237.49	233.30	629.96	626.88	840.82
b. Deferred tax credit	(13.75)	(16.58)	(32.58)	(45.79)	(95.25)	(146.80)
<b>Total tax expense</b>	<b>221.92</b>	<b>220.91</b>	<b>200.72</b>	<b>584.17</b>	<b>531.63</b>	<b>694.02</b>
<b>7. Profit for the period/year [5-6]</b>	<b>625.73</b>	<b>631.59</b>	<b>582.44</b>	<b>1,672.22</b>	<b>1,585.14</b>	<b>2,123.77</b>
<b>8. Other comprehensive income</b>						
<i>Items that will not be reclassified to profit or loss</i>						
Re-measurement gain on defined benefit plans	1.90	2.58	2.50	5.71	10.02	5.58
Income tax effect	(0.44)	(0.57)	(0.72)	(1.32)	(2.50)	(1.24)
<b>Other comprehensive income for the period/year, net of tax</b>	<b>1.46</b>	<b>2.01</b>	<b>1.78</b>	<b>4.39</b>	<b>7.52</b>	<b>4.34</b>
<b>9. Total comprehensive income for the period/year [7+8]</b>	<b>627.19</b>	<b>633.60</b>	<b>584.22</b>	<b>1,676.61</b>	<b>1,592.66</b>	<b>2,128.11</b>
<b>Profit for the period/year attributable to:</b>						
Owners of the Company	621.25	629.08	579.17	1,660.28	1,572.39	2,108.34
Non-controlling interests	4.48	2.51	3.27	11.94	12.75	15.43
<b>Profit for the period/year</b>	<b>625.73</b>	<b>631.59</b>	<b>582.44</b>	<b>1,672.22</b>	<b>1,585.14</b>	<b>2,123.77</b>
<b>Other comprehensive income for the period/year attributable to:</b>						
Owners of the Company	1.46	2.00	1.85	4.38	7.50	4.32
Non-controlling interests	(0.00)	0.01	(0.07)	0.01	0.02	0.02
<b>Other comprehensive income for the period/year</b>	<b>1.46</b>	<b>2.01</b>	<b>1.78</b>	<b>4.39</b>	<b>7.52</b>	<b>4.34</b>
<b>Total comprehensive income for the period/year attributable to:</b>						
Owners of the Company	622.71	631.08	581.02	1,664.66	1,579.89	2,112.66
Non-controlling interests	4.48	2.52	3.20	11.95	12.77	15.45
<b>Total comprehensive income for the period/year</b>	<b>627.19</b>	<b>633.60</b>	<b>584.22</b>	<b>1,676.61</b>	<b>1,592.66</b>	<b>2,128.11</b>
<b>10. Paid-up equity share capital (Face value of Rs. 10 each)</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>
<b>11. Other Equity</b>						<b>9,584.09</b>
<b>12. Earning per share (Face value of share Rs.10 each)</b>						
a. Basic (Rs)	6.12	6.20	5.74	16.36	15.58	20.89
b. Diluted (Rs)	6.12	6.20	5.74	16.36	15.58	20.89
	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	





**Notes :**

- The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issues thereunder, other accounting principles generally accepted in India and guidelines issues by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by Audit Committee and approved by the Board of Directors at their respective meetings held on 24 January 2024. The Statutory Auditors have carried out a limited review on the unaudited consolidated financial results and issued an unmodified report thereon.
- Final dividend for the financial year 2022-23 of Rs. 3 per Equity Share of Rs. 10 each aggregating to Rs. 304.51 million was approved by the shareholders at the 25th Annual General Meeting held on 29 June 2023 and the same was paid on 04 July 2023.
- During the financial year 2022-23, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022.  
The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between the Company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO Expenses Rs. 138.60 million has been adjusted with securities premium as per Companies Act, 2013.  
During the quarter ended 30 September 2023, the Company has received an amount of Rs. 14.70 million towards the Company's share of unspent IPO expenses. The same has been adjusted with securities premium as per Companies Act, 2013. The Board of Directors of the Company in their meeting held on 30 October 2023 has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes, refer column (B) in the table below. After this change amount to be utilised for General corporate purposes is Rs. 576.10 million.

**Details of utilisation of IPO proceeds:**

(Rs. in Millions)

Objects of the issue	Amount as proposed in offer document	Amount to be spent as per offer document up to 31 March 2023 (A)	Reimbursement of Company's share of unspent IPO expenses (B)	Status as at 31 December 2023 for 31 March 2023			
				Revised amount to be spent (C) = (A) + (B)	Utilisation up to 31 December 2023 (D)	Unspent balance as at 31 December 2023 E = (C) - (D)	Reasons for delay in utilisation of IPO Proceeds
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-	400.00	400.00	-	NA
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	1,065.00	-	1,065.00	1,057.44	7.56	Delay in execution of few projects
General corporate purposes	561.40	561.40	14.70	576.10	576.10	-	NA
<b>Total</b>	<b>2,661.40</b>	<b>2,026.40</b>	<b>14.70</b>	<b>2,041.10</b>	<b>2,033.54</b>	<b>7.56</b>	

Net IPO proceeds which were unutilised as at 31 December 2023 were temporarily invested in fixed deposits and held in current account with banks.

- Pursuant to the resolutions passed by the Board on 18 March 2023 and by the Shareholders on 06 May 2023, the Company approved 'Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The Stock Unit Plan 2023 is for issue of employee stock units to eligible employees, which may result in an issuance of a maximum number of 400,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one Equity Share per employee stock unit.

Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held on 14 May 2023 and 07 August 2023, granted 275,000 and 37,414 Stock Units respectively under the Stock Unit Plan 2023 to its eligible employees which shall be exercisable into 312,414 equity shares having face value of Rs.10 each fully paid-up. The exercise price per stock unit shall be the face value of equity shares of the Company i.e., Rs. 10 each. The vested Stock Units shall be exercisable within a period of three months from the date of each vesting. The Stock Units shall vest after the minimum vesting period of one year and not later than the maximum period of five years from the date of grant. The plan is in terms of SEBI SBEB SE Regulations.

- During the financial year 2022-23, the Company won the bid for 2 land parcels in Gurugram, Haryana admeasuring 9,391 Sq. Mtr. - 2.32 acres and 4,987.10 Sq. Mtr. - 1.23 acres, situated in Sector 44 and Sector 56 respectively auctioned by Haryana Shahari Vikas Pradhikaran (HSVP). On 05 July 2023, the Company has received the allotment letters from HSVP, for the allotment of said land parcels to the Company post payment of full consideration of Rs. 1,299.40 million and Rs. 290.40 million for land parcels situated in Sector 44 and Sector 56 respectively.
- The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- The consolidated financial results for the quarter and year to date ended 31 December 2023, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in)
- The consolidated financial results include the financial results of Rainbow Children's Medicare Limited ('the Company') and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited and Rainbow Children's Hospital Private Limited (together called as the "Group").



for and on behalf of the Board of Directors of  
Rainbow Children's Medicare Limited

**Dr. Ramesh Kancharla**  
Chairman and Managing Director  
DIN: 00212270

Place : Hyderabad  
Date : 24 January 2024